Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Phase III results indicate Ergoset's effectiveness and safety

July 26, 1996

Selective beta3-adrenoceptor agonists in Dainippon's pipeline

July 26, 1996

Ibex licenses technology from Centre for Applied Microbiology and Research

July 26, 1996

Celtrix's SomatoKine proven safe in phase I

July 26, 1996

SR-12813: SmithKline Beecham and Symphar's hypocholesterolemic drug

July 26, 1996

Patent collaboration on bone morphogenetic/osteogenetic proteins

July 26, 1996

Boehringer Mannheim reveals acatelin, a novel ACAT inhibitor

July 26, 1996

Isolation of SOX-9 polypeptide encoding gene announced

July 26, 1996

Didronel receives 22nd marketing approval

July 19, 1996

Lea's Shield demonstrates contraceptive efficacy and safety

July 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.